PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)

(2016) Christopher J Edwards et al.   ANNALS OF THE RHEUMATIC DISEASES

Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease

(2016) Alon D. Levin et al.   Journal of Crohns & Colitis

A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial

(2016) M. Cutolo et al.   JOURNAL OF RHEUMATOLOGY

The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE)

(2016) K. Reich et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis

(2016) Paolo Gisondi et al.   Drug Design Development and Therapy

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)

(2015) C. Paul et al.   BRITISH JOURNAL OF DERMATOLOGY

Apremilast: A Review in Psoriasis and Psoriatic Arthritis

(2015) Emma D. Deeks   DRUGS

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

(2015) Kim Papp et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Improvements in patient-reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE

(2015) K.A. Papp et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Etiology and Pathogenesis of Psoriasis

(2015) Wolf-Henning Boehncke   RHEUMATIC DISEASE CLINICS OF NORTH AMERICA

The Pharmacodynamic Impact of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, on Circulating Levels of Inflammatory Biomarkers in Patients with Psoriatic Arthritis: Substudy Results from a Phase III, Randomized, Placebo-Controlled Trial (PALACE 1)

(2015) Peter H. Schafer et al.   Journal of Immunology Research

Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity

(2014) P.H. Schafer et al.   CELLULAR SIGNALLING

Loss of Response to Anti-Tumor Necrosis Factors: What Is the Next Step?

(2014) Shomron Ben-Horin   DIGESTIVE DISEASES

Apremilast: First Global Approval

(2014) Raewyn M. Poole et al.   DRUGS

Cyclic Nucleotide Phosphodiesterases: important signaling modulators and therapeutic targets

(2014) F Ahmad et al.   ORAL DISEASES

Phosphodiesterase 4 and its inhibitors in inflammatory diseases

(2014) S.-L.Catherine Jin et al.   Biomedical Journal

Opportunistic Infections With Anti-Tumor Necrosis Factor-α Therapy in Inflammatory Bowel Disease: Meta-Analysis of Randomized Controlled Trials

(2013) Alexander C Ford et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Therapeutic Strategies in Psoriasis Patients with Psoriatic Arthritis: Focus on New Agents

(2013) Emily Yiping Gan et al.   BIODRUGS

Phosphodiesterase 4-targeted treatments for autoimmune diseases

(2013) Neal Kumar et al.   BMC Medicine

The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab

(2013) Bella Ungar et al.   GUT

Extra-intestinal malignancies in inflammatory bowel disease: Results of the 3rd ECCO Pathogenesis Scientific Workshop (III)

(2013) Fernando Magro et al.   Journal of Crohns & Colitis

Patient-reported Health-related Quality of Life with Apremilast for Psoriatic Arthritis: A Phase II, Randomized, Controlled Study

(2013) V. Strand et al.   JOURNAL OF RHEUMATOLOGY

The Selective Phosphodiesterase 4 Inhibitor Roflumilast and Phosphodiesterase 3/4 Inhibitor Pumafentrine Reduce Clinical Score and TNF Expression in Experimental Colitis in Mice

(2013) Florian Rieder et al.   PLoS One

Pharmacophore Modeling and Virtual Screening for the Discovery of New type 4 cAMP Phosphodiesterase (PDE4) Inhibitors

(2013) Miaomiao Niu et al.   PLoS One

Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled study

(2012) Georg Schett et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study

(2012) K.A. Papp et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial

(2012) Kim Papp et al.   LANCET

Crohn's disease

(2012) Daniel C Baumgart et al.   LANCET

Review article: loss of response to anti-TNF treatments in Crohn’s disease

(2011) S. Ben-Horin et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review

(2011) Vincent Billioud et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Ulcerative Colitis

(2011) Silvio Danese et al.   NEW ENGLAND JOURNAL OF MEDICINE

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose and How to Predict Response?

(2010) Geert R D'Haens et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Phosphodiesterase 4 Inhibitors in Inflammatory Bowel Disease: A Comprehensive Review

(2010) Pooneh Salari-Sharif et al.   CURRENT PHARMACEUTICAL DESIGN

Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects

(2010) Matthieu Allez et al.   Journal of Crohns & Colitis

Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases

(2010) Georg Schett et al.   Therapeutic Advances in Musculoskeletal Disease

Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review

(2009) Javier P Gisbert et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis

(2009) PH Schafer et al.   BRITISH JOURNAL OF PHARMACOLOGY

CC-10004 but not thalidomide or lenalidomide inhibits lamina propria mononuclear cell TNF-α and MMP-3 production in patients with inflammatory bowel disease

(2009) J.N. Gordon et al.   Journal of Crohns & Colitis

Inhibition of cAMP Degradation Improves Regulatory T Cell-Mediated Suppression

(2009) T. Bopp et al.   JOURNAL OF IMMUNOLOGY

Discovery of (S)-N-{2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide (Apremilast), a Potent and Orally Active Phosphodiesterase 4 and Tumor Necrosis Factor-α Inhibitor

(2009) Hon-Wah Man et al.   JOURNAL OF MEDICINAL CHEMISTRY

Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown

(2009) Miles D. Houslay   TRENDS IN BIOCHEMICAL SCIENCES

Enhanced PDE4B expression augments LPS-inducible TNF expression in ethanol-primed monocytes: relevance to alcoholic liver disease

(2008) Leila Gobejishvili et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Cyclic AMP

(2008) Carlos H. Serezani et al.   AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY

An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast

(2008) A. B. Gottlieb et al.   CURRENT MEDICAL RESEARCH AND OPINION

Tetomilast suppressed production of proinflammatory cytokines from human monocytes and ameliorated chronic colitis in IL-10-deficient mice

(2008) Hitoshi Ichikawa et al.   INFLAMMATORY BOWEL DISEASES

A selective phosphodiesterase 4 (PDE4) inhibitor Zl-n-91 suppresses IL-17 production by human memory Th17 cells

(2008) Ruihong Ma et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

NF-κB in inflammatory bowel disease

(2008) I. Atreya et al.   JOURNAL OF INTERNAL MEDICINE

Induction and effector functions of TH17 cells

(2008) Estelle Bettelli et al.   NATURE